Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Inc.

www.biogen.com

Latest From Biogen Inc.

Another Alzheimer's Setback As Roche And Lilly Drugs Fail

As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.

Neurology Clinical Trials

Biogen's Tecfidera Safe Following IPR Decision – For Now

Tecfidera accounts for nearly one-third of Biogen's revenues, so the patent decision relieves one overhang for the company. However, other ANDA challenges are ongoing.
Intellectual Property Legal Issues

Global Biopharma R&D Productivity And Growth Ranking

An analysis of the R&D productivity of the world’s 30 largest public pharmaceutical companies reveals an overall drop in R&D productivity, but this should not hide the fact that some companies are still performing extremely well.

BioPharmaceutical Strategy

Formycon Delay Pushes Back Coherus’ Ranibizumab

Formycon and Bioeq’s US filing for a biosimilar ranibizumab rival to Lucentis has been delayed after the FDA requested further data following a manufacturing change. Rights to the biosimilar have been licensed exclusively to Coherus in the US.

Biosimilars Regulation
See All

Company Information

UsernamePublicRestriction

Register